Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development.
Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal AL, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW. Dickinson MJ, et al. Among authors: shune l. Cancer Discov. 2023 Sep 6;13(9):1982-1997. doi: 10.1158/2159-8290.CD-22-1276. Cancer Discov. 2023. PMID: 37249512 Free PMC article.
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Haverkos B, et al. Among authors: shune l. Blood Adv. 2023 Oct 24;7(20):6339-6350. doi: 10.1182/bloodadvances.2023010330. Blood Adv. 2023. PMID: 37530631 Free PMC article. Clinical Trial.
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.
Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Zanwar S, et al. Among authors: shune l. J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4. J Hematol Oncol. 2024. PMID: 38845015
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World Experience.
Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson L, Fererri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Khouri J, et al. Among authors: shune l. Transplant Cell Ther. 2024 Jun 2:S2666-6367(24)00437-8. doi: 10.1016/j.jtct.2024.05.025. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38834151
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy.
Dima D, Abdallah AO, Davis JA, Awada H, Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, Mahmoudjafari Z, Williams L, Faiman B, McGuirk JP, Sauter CS, Ahmed N, Khouri J, Hashmi H. Dima D, et al. Among authors: shune l. Blood Cancer J. 2024 May 31;14(1):90. doi: 10.1038/s41408-024-01068-w. Blood Cancer J. 2024. PMID: 38821914 Free PMC article.
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Afrough A, et al. Among authors: shune l. Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0. Blood Cancer J. 2024. PMID: 38609386 Free PMC article. No abstract available.
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
Shahzad M, Khalid MF, Amin MK, Ammad-Ud-Din M, Ilyas U, Mushtaq AH, Butt A, Anwar I, Chaudhary SG, Ahmed N, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: shune l. Hematol Oncol Stem Cell Ther. 2024 Mar 22;17(2):88-94. doi: 10.56875/2589-0646.1118. Hematol Oncol Stem Cell Ther. 2024. PMID: 38560970
Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience.
McGuirk M, Shahzad M, Amin MK, Khan MA, Bellman P, Mudaranthakam DP, DeJarnette S, Lutfi F, Ahmed N, Bansal R, Abdelhakim H, Gorsline C, Shoemaker DM, Abdallah AO, Shune L, Abhyankar SH, Singh AK, McGuirk JP, Mushtaq MU. McGuirk M, et al. Among authors: shune l. Transpl Immunol. 2024 Jun;84:102039. doi: 10.1016/j.trim.2024.102039. Epub 2024 Mar 19. Transpl Immunol. 2024. PMID: 38513813 Free article.
Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes TM, Holstein SA, Anderson LD Jr, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Nooka AK, et al. Among authors: shune l. Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19386. Online ahead of print. Br J Haematol. 2024. PMID: 38504552
74 results